Merck presents new data on cardiovascular disease at ESC Congress 2025
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
KER-065 is a novel ligand trap comprised of a modified ligand-binding domain derived from activin receptor type IIA and activin receptor type IIB
The company is bringing precision therapies for gynaecological cancers
Astaxanthin is a powerful antioxidant and red-orange carotenoid pigment found in various aquatic organisms
The accelerated approval is supported by results from part 1 of the ESSENCE trial
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Subscribe To Our Newsletter & Stay Updated